↑  Read the latest from the desks  ·  fresh intelligence, published daily✦Quiet reading✦No ads, ever

✦Corporate brand & media services✦Made in Virginia Beach since 1997✦

Natural Alternatives International: Rotting at the dock (four or more warning signs)Rotting at the dock

Natural Alternatives International $NAII

Grew revenue 9.7% in FY2026 to $143 million, operating margin -13.2% against a 0.7% median for medicinal chemicals & botanical products, equity 39.5% of assets.

Last filing10-Q, 13 Nov 2026

Next year, 80%$114M–$185M
Growth, on the year9.7%
Operating margin−13.2%
Equity of assets39.5%
Credibility57%
Track record8 of 12
Your call, sealedNext year’s revenue, your range. Sealed now, graded when the annual report lands.
Edgarette’s full reading · exposure, experience, soundness, credibility, range

🫧 Edgar looked up NATURAL ALTERNATIVES INTERNATIONAL INC ($NAII). Last filing: 10-Q, 2026-11-13. 4 event filings (8-K) in the past twelve months.

🔖 Exposure: revenue $142.5M (FY2026). Experience: revenue up 9.7% on the year, down 4.4% a year over 4 years; operating margin -13.2%, down from -6.7%. Soundness: equity 39.5% of assets, return on equity -41.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $113.9M and $184.5M next year (method v4.1: its own 5-year record of growth weighed at 57% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $100.8M to $209.5M. A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, medicinal chemicals & botanical products): operating margin -13.2% against a 0.7% median; growth 9.7% against 1.7%.

Read from its own SEC filings · nothing written, nothing inferred

NATURAL ALTERNATIVES INTERNATIONAL INC against its own record and its peers
Operating marginPeer median 0.7%-13.2%Revenue, on the yearPeer median 1.7%9.7%Equity of assetsPeer median 33.3%39.5%Return on equity-41.4%Gold tick: the median of 8–8 peers with $50M+ revenue in medicinal chemicals & botanical products

Speed and cash · fiscal 2025

Cash Compass🍂 Fading · slow and jumpy, lagging its peers
Inside viewTurns 4.6% of revenue into operating cash; revenue shrinking 8.8% a year over three years; no common dividend.
Outside viewAmong $100M-1B companies: 37th percentile for cash, 14th for growth. cash growth

Both views must agree for a label · a description, not advice.

Cash flow (op · inv · fin · free)−$9M · −$4M · $8M · −$13M
Investment book (cash · short · long)$7M · — · — · current ratio 1.73
Revenue swing · equity of assets17.9% · 43.7%

Natural Alternatives International is growing slower than its size class, with revenue that swings more. Its own audited SEC figures.

The figures, as filed

Fiscal year end2026-06-30
Revenue$143M
Revenue, on the year9.7%
Revenue, a year over the record−4.4%
Operating margin−13.2%
Operating margin, prior year−6.7%
Net margin−14.5%
Research and development$2M · 1.6% of revenue
Total debt—
Equity of assets39.5%
Return on equity−41.4%
Payout of profit—
Dividend per share—
Earnings per share$-3.43
Book value per share$8.29
Revenue per share$23.64
Shares outstanding6,027,816
Audited years read5

Peers: the median of 10 filers with $50M+ revenue in medicinal chemicals & botanical products.

Classic signals · fiscal 2026Altman Z″ 2.12 grey zone 1968Piotroski F 3 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals -8.5% earnings backed by cash 1996DuPont ROE -35% = margin -14.5% × turns 1.02 × leverage 2.35

What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →

Health HarborNatural Alternatives International sails as Rotting at the dock4 warning signs

Health watch · 12 monthsLate quarterly report noticeDirector or officer change ×2

Versus peersoperating margin −13.2% vs a 0.7% median · revenue growth 9.7% vs 1.7% · cash beats 37% of its size class · growth beats 14% 10 medicinal chemicals & botanical products filers

Trend · last year to this▼operating margin −6.7% → −13.2% · ▲revenue $129.9M → $142.5M · 5-year revenue: $171.0M · $154.0M · $113.8M · $129.9M · $142.5M

See all 14 medicinal chemicals & botanical products companies on POPS4 sorted from the newest ship to the boat at the dock
#CompanyConditionOperating marginRevenue growthSales
1New shipUsana Health SciencesUSNANew ship4.0%8.3%$925.3M
2Sound shipMarimedMRMDSound ship−1.8%1.3%$159.8M
3Sound shipCronos GroupCRONSound ship−9.0%19.5%$193.4M
4Weathered boatFitlife BrandsFTLFWeathered boat12.4%26.4%$81.5M
5Weathered boatTilray BrandsTLRYWeathered boat−6.9%11.5%$915.5M
6Weathered boatHealthy ExtractsHYEXWeathered boat—44.9%$4.5M
7Rotting at the dockMannatechMTEXRotting at the dock−0.4%−8.3%$108.0M
8Rotting at the dockNatural Alternatives InternationalNAII · this companyRotting at the dock−13.2%9.7%$142.5M
9Rotting at the dockTwinlab Consolidated Holdings1590695Rotting at the dock−15.2%−14.3%$11.7M
10Rotting at the dockLeef BrandsLEEEFRotting at the dock−21.8%22.1%$34.8M
11Rotting at the dockSynergy ChcSNYRQRotting at the dock−27.8%−12.8%$30.4M
12Rotting at the dockAdia MedADIARotting at the dock−52.3%10879.7%$0.7M
13Rotting at the dockNutra PharmaNPHCRotting at the dock−567.7%4.6%$0.3M
14Rotting at the dockAiboticsAIBTRotting at the dock−84501.7%—$0.0M

From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.

Tied up at the dock.

🌊 Visit the Bay →
The warning signs
  • Filed late quarterly report notice in the last 12 months
  • Slow and jumpy growing slower than its size class, with revenue that swings more
  • Operating loss a margin of -13.2% in FY2026
  • Free cash flow was negative capital spending outran operating cash (-$12.6M in FY2026)

Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.

Brand success factors · calendar 2025

The Trillion Score: 364

Exponential Success Score

Built on over $200 trillion of sworn revenue, 13 years of data, 770,002 figures. Sealed by Edgarette.

How The Trillion Score works. We read eight measures of success from Natural Alternatives International's own SEC filings and test each one against the public companies in its field, here pharmaceutical preparations. The longer and fuller the record, the more weight those results carry. A model built on past filings then turns them into the odds of thriving, which means outgrowing the field for three years without a severe decline. A score of 500 is about average, and every 100 points doubles the odds. Every company is ranked on this same scale.

What it says here. At 364, Natural Alternatives International's odds of thriving come to 18%, against about 37% for the typical filer. It meets 0 of 7 success points.

364The Trillion Score
18%modeled odds of thriving over three years
HighFall Risk
#182 of 182rank in its field
#2,775 of 2,824rank across all filers

What the score means

The higher the score, the more often companies went on to thrive. At this level, about 31 of every 100 did.

31%Under 450This company: 36435%450 to 49938%500 to 54944%550 to 59957%600 and up

Share of companies that beat their field for three years with no severe decline, tested on 2019 to 2022 filings.

Fall Risk: High

Separate from the score, this asks what could go wrong: the odds of sales falling 30% or the filings stopping within three years. In the tests, about 41 of every 100 companies in the High band did. That is the group's history, not a forecast for this company.

MoneyIt keeps about 2 cents of free cash from each sales dollar after paying for its plants and equipment.cash negative over five years
SwingsIn its worst fifth of years, sales fell about 30% a year.-30.3% a year
Filed eventsIn the last two years it told the SEC about 1 filings on leadership or auditor changes.1

The eight success points

PointWhat it meansPlace in field
SpeedSales grew slower than much of its field.13 of 100Not yet
SteadinessGrowth swung a lot for what it delivered.17 of 100Not yet
Price premiumIt keeps less of each sales dollar than the leaders in its field.2 of 100Not yet
Margin stays above the fieldIts margin has not held above the field for long.3 of 100Not yet
Moat half-lifeIts margin edge is fading fast, or it has none yet.4 of 100Not yet
Brand spend yieldNot filed.
Learning curveCosts have not fallen much as a share of sales as it grew.30 of 100Not yet
Climb in the fieldIt has not been moving up the size ranks in its field.10 of 100Not yet

Price premium -$78M is the extra gross profit over a field-median margin. Momentum -$2M is gross profit times growth above the field's pace.

The actuarial view

CredibilityWith 8 years of filings, the record earns 61% of the weight. The rest stays at the middle of the field.0.61
Severe decline, class DAbout 34 of every 100 companies with this many points fell 30% or stopped reporting within three years.34.3%
Actual vs expectedSales are 40% lower than if it had simply kept pace with its field.0.60

Top of its field: #1 Mannkind · #2 Biocryst Pharmaceuticals · #3 Corcept Therapeutics · #4 Kiniksa Pharmaceuticals International · #5 Eli Lilly

Ranked by The Trillion Score. See the method and score your own brand. Tested on 2019 to 2022 filings. Odds, class and Fall Risk figures are the experience of similar filers, not a forecast for this company. A statistical description of past filings, not a rating or advice.

Recent filings
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.

Try InstagramSpriteHokaDisneyGatoradee.l.f.

Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·

1 · Follow

Follow their filings

Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.

On Bluesky: follow Edgar & Edgarette.

2 · Price it

A new leader’s rebrand and launch

Priced live by the same engine as our estimator, from the catalogue at wholesale.

Price the printing · Open the full estimator

✦ Build the kit yourself
3 · Confirm

Check it with Jenny

Most buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.

Jenny Huang Goodman MPA MSc MHSA, Principal

Book a time info@pops4.com
Independence. Every range, flag and score on these boards is identical for everyone. Clients of POPS4 or Hako Shikin receive no different numbers, no earlier access and no say in what is published. The service lines shown beside each board describe work we do; they never change the data. For reviewers: Method · Terms of use · Status
Free · unsponsored · source-linked

Clean data. No ads. Not now, not later.

Nine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.

Every row is a filing.Straight from the company's own SEC document, linked. Nothing written, nothing inferred.
Nobody is watching you read.No ad trackers, no cookies from us. Our page counts are cookieless.
One email, one job.Watch a company and we hold that address for the alert alone. One tap ends it. Never shared, never passed on.
The house pays for this.Corporate event programs, corporate supplies and branded merchandise, since 1997. That is what funds the desks, under the house's own vendor standards.
Free to reuse with credit · CC BY 4.0 · how the boards are built
Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners.